Ctrl Worx Watch List › Company

GeneDx Holdings Corp. (WGS): material weakness open 302 days

By , Ctrl Worx™. Built from its own SEC filings. How the Clock works.

GeneDx Holdings Corp. reported ineffective internal control over financial reporting because of a material weakness in 1 filing since Feb 23, 2026. It stated one or more material weaknesses in 2 more SEC filings that gave no conclusion on whether that control is effective. The latest was its 10-Q for the period ended Jun 30, 2026.

Ctrl Worx Watch List™ status

On the Clock
0.8 yearsopen since Dec 31, 2025
10-Q, Aug 3, 2026latest filing that reports the weakness. Read it on SEC EDGAR
#995 of 1,250on the Clock by time open, tied with 119 other companies that share its start date. See the Clock

Still filing, and no annual report of its own says the weakness is fixed.

Checked against SEC EDGAR: Oct 29, 2026 · Entry #11629

Filings with a weakness17
First in our dataJul 21, 2021
AuditorERNST & YOUNG LLP

Causes the company named

ITGC: change management · 10Financial close and reporting · 9ITGC: user access · 8Accounting expertise and resources · 8Segregation of duties · 6Revenue recognition · 3Complex or non-routine accounting · 3ITGC: general · 3Entity-level and governance · 2Inventory · 1

What the latest filing says

Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of June 30, 2026, because of the material weakness in internal control over information technology general controls, or ITGCs previously identified for the year ended December 31, 2025, as described below, has not been fully remediated as of June 30, 2026. 34 Table of Contents Previously Reported Material Weakness A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. As described in more detail in Item 9A. “Controls and Procedures” of our 2025 Form 10-K, we identified a material weakness in internal control related to deficiencies in the design and operating effectiveness of IT general controls related to segregation of duties in the program change management process for a single IT [...]

From the controls section of the 10-Q filed Aug 3, 2026. Read the full filing on SEC EDGAR.

Company response: GeneDx Holdings Corp. can send a statement or a link to its remediation update to russell@ctrlworx.com. We post it here, unedited and dated.

Filings

FiledFormPeriodControlsCausesFiling
Aug 3, 202610-QJun 30, 2026Material weakness stated, no ICFR conclusionSegregation of duties; ITGC: change managementEDGAR
May 4, 202610-QMar 31, 2026Material weakness stated, no ICFR conclusionITGC: user access; ITGC: change management; Revenue recognitionEDGAR
Feb 23, 202610-KDec 31, 2025Not effectiveITGC: change management; Revenue recognitionEDGAR
Feb 20, 202510-KDec 31, 2024EffectiveEDGAR
Oct 29, 202410-QSep 30, 2024Material weakness stated, no ICFR conclusionITGC: user access; ITGC: change managementEDGAR
Jul 30, 202410-QJun 30, 2024Material weakness stated, no ICFR conclusionSegregation of duties; ITGC: user access; ITGC: change managementEDGAR
Apr 29, 202410-QMar 31, 2024Material weakness stated, no ICFR conclusionSegregation of duties; ITGC: user access; ITGC: change managementEDGAR
Feb 23, 202410-KDec 31, 2023Not effectiveSegregation of duties; ITGC: user access; ITGC: change managementEDGAR
Nov 3, 202310-QSep 30, 2023Material weakness stated, no ICFR conclusionFinancial close and reporting; Accounting expertise and resourcesEDGAR
Aug 8, 202310-QJun 30, 2023Not effectiveFinancial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
May 9, 202310-QMar 31, 2023Not effectiveFinancial close and reporting; Accounting expertise and resourcesEDGAR
Mar 16, 202310-KDec 31, 2022Not effectiveFinancial close and reporting; Accounting expertise and resources; ITGC: user access; ITGC: change managementEDGAR
Nov 14, 202210-QSep 30, 2022Material weakness stated, no ICFR conclusionFinancial close and reporting; Accounting expertise and resources; ITGC: user access; ITGC: change managementEDGAR
Aug 15, 202210-QJun 30, 2022Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; Complex or non-routine accounting; ITGC: generalEDGAR
May 12, 202210-QMar 31, 2022Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; ITGC: generalEDGAR
Mar 14, 202210-KDec 31, 2021Not effectiveFinancial close and reporting; Accounting expertise and resources; Complex or non-routine accounting; ITGC: user access; ITGC: change management; Entity-level and governance; Revenue recognition; InventoryEDGAR
Nov 15, 202110-QSep 30, 2021Not effectiveFinancial close and reporting; ITGC: generalEDGAR
Jul 21, 202110-QJun 30, 2021Material weakness stated, no ICFR conclusionComplex or non-routine accountingEDGAR
May 5, 202110-K/ADec 31, 2020Not effectiveComplex or non-routine accounting; Revenue recognitionEDGAR

Others on the Clock in the same industry

By SEC industry code: 8000, Services-Health Services, then related codes.

Follow WGS for free

Get an email when GeneDx Holdings Corp files a 10-K or 10-Q that reports a material weakness, or says its controls are effective again.

Want the next one the day it's filed?

MW Pro sends an alert the day a company you follow reports a material weakness or says it fixed one. Founding price $990 a year.

Join the MW Pro waitlistLook up any company in Controls Radar™

Watch List Weekly: new material weaknesses, fixes and the longest-running cases, every Monday.

One email to confirm, then one email each Monday. Every email has a one-click unsubscribe. Privacy policy

Based on public SEC filings. Causes are grouped into standard categories by Ctrl Worx. The filings are the authority. Ctrl Worx is not affiliated with GeneDx Holdings Corp. or the SEC. Not investment advice. Why you can rely on the Watch List.